Physician profile
Amy Heyman
NPI 1437289766
$2,310.00
in general payments reported to CMS, 2019-2025
31 companies · $266 in 2025
The $266 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $491 · 2021: $436 · 2022: $193 · 2023: $334 · 2024: $312 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $912.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Renovia INC | $375.69 | 2019-2021 | |
| Abbvie INC. | $302.30 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $232.28 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $158.68 | 2022-2025 | |
| Allergan, INC. | $158.64 | 2019-2021 | |
| Astellas Pharma US INC | $106.70 | 2023-2025 | Veozah, Myrbetriq |
| Aspira Women'S Health INC | $99.60 | 2021-2024 | Ova1 |
| Daiichi Sankyo INC. | $99.19 | 2023-2024 | Injectafer |
| Coopersurgical, INC. | $88.55 | 2021-2023 | Paragard T 380a |
| Therapeuticsmd, INC. | $82.47 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $78.70 | 2023-2025 | Gemtesa |
| Alydia Health | $65.08 | 2021 | |
| Shield Therapeutics INC | $62.15 | 2024 | |
| Axonics, INC. | $50.54 | 2023-2024 | Axonics |
| Smith+Nephew, INC. | $44.57 | 2019-2023 | Pico |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $44.09 | 2020-2025 | Gardasil 9 |
| Kci USA, INC. | $43.74 | 2019-2023 | Prevena, V.A.C. Veraflo, V.A.C.Ulta |
| Hologic Sales and Service, LLC | $23.03 | 2021 | |
| Exeltis, USA INC. | $22.64 | 2020 | |
| Amag Pharmaceuticals, INC. | $18.20 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $18.06 | 2023 | Kristalose |
| Mylan Pharmaceuticals INC. | $16.90 | 2021 | |
| Organon LLC | $16.63 | 2021 | |
| Medtronic, INC. | $16.59 | 2022 | |
| Galderma Laboratories, L.P. | $16.15 | 2023 | |
| Distalmotion US | $15.07 | 2025 | Dexter L6 Robot |
| Ethicon US, LLC | $14.50 | 2023 | Stratafix, Dermabond, Vistaseal |
| Avion Pharmaceuticals | $13.69 | 2022 | |
| Millicent US INC | $13.42 | 2024 | Femring, Intrarosa |
| Evofem Biosciences, INC. | $12.15 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Heyman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.